Canine Melanoma Combination

About HylaPharm

HylaPharm is a private, preclinical-stage biotech leveraging a proprietary hyaluronan-based nanoconjugate platform for localized drug delivery. The company's lead programs focus on intratumoral delivery of chemotherapeutics (like cisplatin) and immunomodulators to stimulate anti-tumor immunity, with compelling proof-of-concept data from spontaneous canine cancer models. Its dual strategy targets the significant unmet need in human immuno-oncology, where many patients are resistant to checkpoint inhibitors, while also addressing the veterinary oncology market. The company has been funded through SBIR grants and angel investment.

Therapeutic Areas